These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 11847951)

  • 1. FDA adverse event reports on statin-associated rhabdomyolysis.
    Omar MA; Wilson JP
    Ann Pharmacother; 2002 Feb; 36(2):288-95. PubMed ID: 11847951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysis.
    McAdams M; Staffa J; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2008 Mar; 17(3):229-39. PubMed ID: 18175291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
    Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2007 Feb; 99(3):379-81. PubMed ID: 17261402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
    Chang JT; Staffa JA; Parks M; Green L
    Pharmacoepidemiol Drug Saf; 2004 Jul; 13(7):417-26. PubMed ID: 15269925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis.
    Psaty BM; Furberg CD; Ray WA; Weiss NS
    JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
    Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
    JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhabdomyolysis and statins: A pharmacovigilance comparative study between statins.
    Montastruc JL
    Br J Clin Pharmacol; 2023 Aug; 89(8):2636-2638. PubMed ID: 37186323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of a data mining signal for amyotrophic lateral sclerosis and statins detected in FDA's spontaneous adverse event reporting system.
    Colman E; Szarfman A; Wyeth J; Mosholder A; Jillapalli D; Levine J; Avigan M
    Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1068-76. PubMed ID: 18821724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhabdomyolysis a result of azithromycin and statins: an unrecognized interaction.
    Strandell J; Bate A; Hägg S; Edwards IR
    Br J Clin Pharmacol; 2009 Sep; 68(3):427-34. PubMed ID: 19740401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.
    Jones PH; Davidson MH
    Am J Cardiol; 2005 Jan; 95(1):120-2. PubMed ID: 15619408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statin-associated myopathy.
    Thompson PD; Clarkson P; Karas RH
    JAMA; 2003 Apr; 289(13):1681-90. PubMed ID: 12672737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyolysis and HMG-CoA reductase inhibitors.
    Omar MA; Wilson JP; Cox TS
    Ann Pharmacother; 2001 Sep; 35(9):1096-107. PubMed ID: 11573861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
    Holoshitz N; Alsheikh-Ali AA; Karas RH
    Am J Cardiol; 2008 Jan; 101(1):95-7. PubMed ID: 18157972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rhabdomyolysis reports show interaction between simvastatin and CYP3A4 inhibitors.
    Rowan C; Brinker AD; Nourjah P; Chang J; Mosholder A; Barrett JS; Avigan M
    Pharmacoepidemiol Drug Saf; 2009 Apr; 18(4):301-9. PubMed ID: 19206087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.
    Amend KL; Landon J; Thyagarajan V; Niemcryk S; McAfee A
    Ann Pharmacother; 2011 Oct; 45(10):1230-9. PubMed ID: 21917557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyolysis risk from the use of two-drug combination of antidyslipidemic drugs with antihypertensive and antidiabetic medications: a signal detection analysis.
    Gosho M
    Fundam Clin Pharmacol; 2019 Jun; 33(3):339-346. PubMed ID: 30575126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of drug-associated rhabdomyolysis: analysis of 8,610 cases reported to the U.S. Food and Drug Administration.
    Oshima Y
    Intern Med; 2011; 50(8):845-53. PubMed ID: 21498932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Withdrawal of cerivastatin revealed a flaw of post-marketing surveillance system in the United States].
    Saito M; Hirata-Koizumi M; Miyake S; Hasegawa R
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):41-5. PubMed ID: 16541751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
    Lee AJ; Maddix DS
    Ann Pharmacother; 2001 Jan; 35(1):26-31. PubMed ID: 11197581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayer's response to "potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis".
    Piorkowski JD
    JAMA; 2004 Dec; 292(21):2655-7; discussion 2658-9. PubMed ID: 15572725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.